Adicet Bio reports incentive grants pursuant to Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that it will award incentive awards on August 30, 2024.

Adicet hired three individuals in August 2024. In total, Adicet granted the new employees nonqualified stock options to purchase 30,600 shares of Adicet common stock with an exercise price of $1.46 per share, the closing price of Adicet common stock as reported by Nasdaq on August 30, 2024. One-quarter of the shares underlying each employee's option will vest on the one-year anniversary of each recipient's employment start date, and thereafter the remaining three-quarters of the shares underlying each employee's option will vest in thirty-six substantially equal monthly installments such that the shares underlying each employee's option granted will fully vest on the fourth anniversary of the recipient's employment start date, in each case subject to the continued employment of each such employee with Adicet on such vesting dates.